Laboratory medicine professionals worldwide, working as part of interdisciplinary teams, are critical in detecting illnesses early when treatment is most effective. In particular, screening programs combined with patient education can be especially effective at identifying illnesses in individuals who otherwise might be overlooked. The initiatives highlighted below, which have been recognized by the UNIVANTS of Healthcare Excellence program, demonstrate the importance of screening and patient-centered improvement initiatives in improving patient outcomes.
Four interdisciplinary teams have been recognized as 2026 Teams of Distinction through the UNIVANTS of Healthcare Excellence program, which was created through a partnership between Abbott, the Association for Diagnostics & Laboratory Medicine, and other leading healthcare organizations. UNIVANTS has also recognized four other care teams in 2026 with Recognition of Achievement. This prestigious global awards program honors these teams for collaborating across disciplines to transform healthcare delivery.
Read on to learn more about the eight Teams of Distinction and Achievement and the important work they are doing to improve patient care.
Transforming cervical cancer screening
Cervical cancer remains a significant health disparity issue in the United States, with medically underserved populations, particularly low-income, minority, and rural communities, experiencing higher incidence, later-stage diagnosis, and poorer outcomes. Bergen New Bridge Medical Center (Paramus), the largest hospital in New Jersey and a safety-net facility, noticed a concerning number of patients falling out of compliance with routine cervical cancer screening guidelines due in part to social determinants of health, including transportation barriers and anxiety or historical distrust regarding traditional speculum examinations, according to Ilham Atir, who is a laboratory director.
In August 2023, the hospital’s Clinical Laboratory Service integrated the High-Risk Extended HPV Genotype Assay into standard practice and paired it with a patient-friendly, Food and Drug Administration-approved self-collection process. The new assay individually identifies all 14 high-risk human papillomavirus (HPV) types, versus the traditional broad HPV screening.
“We realized if we waited for patients to come to us for Pap smears, many would continue to slip through the cracks until it was too late,” Atir said. “The impetus was a commitment to shift from a reactive healthcare model to a proactive, barrier-reducing strategy centered around patient empowerment and high-sensitivity diagnostics.”
Within the first year of making these changes, a total of 1,177 women (ages 21-76) were screened using an endocervical brush spatula or broom device, followed by a standard physician-collected cervical sample or self-collect. Both samples were analyzed using real-time PCR. All of the women screened had valid results, with a 3% prevalence of high-risk HPV (hrHPV) in self-collected samples and 3.2% prevalence in physician-collected samples. Those who tested positive received follow-up care.
Implementation of the initiative came with significant operational and cultural hurdles, according to Atir. “Our primary challenge was the transition to primary HPV screening and self-collection workflows,” she said. “Providers were accustomed to traditional cytology, and lab operations required validation of new high-throughput assays capable of seamlessly integrating into our existing electronic health record systems.”
Patient education was vital, with the development of culturally sensitive communication materials in multiple languages to normalize self-collection options and ensure patients understood an HPV self-collection kit was just as clinically reliable for risk stratification as a clinician-collected sample when using validated assays.
The team, which is the only U.S. recipient that has been recognized by UNIVANTS with Distinction in 2026, has fundamentally transformed screening capture rates, allowing the lab to reach individuals who had not been screened in 5 years or more, or in some cases, ever. Screening and follow-up visits have risen by 79.3%, and patient satisfaction with women’s health visits has increased by 14%. In addition, there has been a 13% jump in appointments for women’s health services, and a 21% reduction in no-show follow-up visits.
“Our findings demonstrate that embedding low-barrier, high-sensitivity primary HPV screening into primary care can radically alter population health metrics,” Atir said. “The financial impact is substantial, both from a direct operational standpoint and downstream. By catching high-risk HPV infections and treating high-grade squamous intraepithelial lesions early through outpatient pathways, we drastically reduce the utilization of high-acuity hospital resources. This has resulted in savings of $3.7 million between 2024 to 2025 at the medical center.”
Detecting unmet heart failure risk
Cardiovascular diseases leading to heart failure are a leading cause of death globally, and in Japan, are the second leading cause of death. In Izumiotsu-shi, a city in Osaka, hospitals and community clinics had previously established a collaborative approach to prevent heart failure recurrence, according to Akihisa Hanatani, vice hospital director of Izumi-shi Medical Center. Through multidisciplinary collaboration, they focused on optimizing pharmacological treatment and providing patient education, particularly regarding self-management.
“Although these efforts had achieved a certain degree of success, we recognized that reducing the overall burden of heart failure would be difficult without also addressing the prevention of new-onset heart failure,” Hanatani said. “This recognition led us to introduce BNP [B-type natriuretic peptide] testing as a means of identifying individuals at risk at an earlier stage of the disease.”
While BNP testing is widely used in clinical practice to support the diagnosis and management of patients with heart failure, there was initially insufficient evidence regarding its effectiveness for the early identification of individuals at risk of heart failure. As a result, hospital leaders initially faced difficulties in gaining the support of the local government, explained Hanatani.
To address this issue, the Izumi City Medical Association in 2022 took the lead in conducting an investigator-initiated study, the IZUMI FIND HF study. Using natriuretic peptide testing, the study found that approximately 11% of the participants were considered likely to have heart failure while about 26% were considered to have pre-heart failure.
“Based on these findings, the Izumi City Medical Association requested formal funding to add BNP to the municipal health checkup program,” Hanatani said. “Following approval, BNP testing was introduced into the health checkup program in 2024.”
In 2024, approximately 20% of individuals (480) who underwent BNP testing as part of the health checkup had BNP levels above the predefined reference threshold, which was higher than had been anticipated. Among those who subsequently underwent further medical evaluation, 5.4% (17) were newly diagnosed with heart failure, and 16.8% (53) were identified as having suspected heart failure. Thereafter, these individuals received appropriate treatment.
“Our findings demonstrate that among members of the general population who had not previously been diagnosed with heart failure, a proportion had either risk factors for heart failure or may already have had undiagnosed heart failure,” Hanatani said. “This is an important finding because early identification of these individuals and initiation of appropriate treatment may help prevent the development of heart failure and reduce the risk of disease progression.”
The BNP testing initiative has saved an estimated 19 million yen (about $123,000) based on prevention of hospitalizations, according to Hanatani. The initiative is relatively simple to implement. However, if the cost of BNP testing is to be covered as part of a municipal health checkup program, local funding is likely needed, which Hanatani sees as the greatest barrier to implementation. It is also important to establish a system for collecting follow-up data and implementing subsequent evaluations of individuals who are identified as requiring further medical assessment.
“Overcoming these barriers requires both securing a sustainable budget and close collaboration between the local medical association and the local government,” Hanatani said. UNIVANTS has recognized the Izumi team with Distinction.
Improving anticoagulant therapy
In response to challenges faced by patients receiving long-term oral anticoagulant therapy, KIMSHEALTH Hospital in Trivandrum, India, created a Nurse-Led Oral Anticoagulation Clinic (NL-OACC) in 2018. According to Maj. Beena C. A., general manager of nursing, many patients had limited understanding of their medication, international normalized ratio (INR) monitoring requirements, dietary interactions, and warning signs of complications.
“These gaps contributed to preventable thromboembolic and hemorrhagic events, frequent physician visits, hospital admissions, and increased financial burden,” she explained. “We recognized the need for a structured, patient-centered model that would provide continuous education, close monitoring, and readily accessible support.”
The goal of the clinic was to provide safe, consistent, and zero-cost monitoring for all patients receiving anticoagulation therapy. The interdisciplinary approach ensured that every patient received comprehensive care tailored to their specific risks and needs. Nurses played a leading role in delivering daily clinical operations, monitoring laboratory results, identifying early warning signs, adjusting doses in consultation with physicians, and offering 24/7 telephone assistance.
The clinic significantly improved patient safety and clinical outcomes, according to Beena. “Through structured education, regular monitoring, prompt identification of INR variations, and timely dose adjustments, oral anticoagulant-related complications steadily decreased over the study period,” she said. “Most notably, both thromboembolic and hemorrhagic complications were completely eliminated by 2024.”
Over the study period, complications declined from 15 cases in 2018 to zero in 2024, representing a 100% reduction. These results were achieved while patient volumes continued to increase, highlighting the scalability, sustainability, and effectiveness of nurse-led care.
“The findings are highly significant because they demonstrate that a nurse-led model can achieve outstanding clinical and economic outcomes in a high-risk population,” Beena said.
The initiative, which was recognized with honors of Distinction by the UNIVANTS program, resulted in substantial cost savings for both patients and the healthcare system. According to Beena, the estimated annual expenditure associated with managing oral anticoagulation-related complications decreased from approximately 3.2 million Indian Rupees (about $33,354) in 2018 to zero by 2024. Patients also benefited from reduced travel expenses, fewer physician consultations for routine dose adjustments, fewer hospital admissions, and reduced loss of work time.
The roll-out had some resistance, said Beena. “The biggest challenge was earning clinical buy-in because some physicians were understandably cautious about a nurse-led model taking ownership of a high-risk drug category like anticoagulants, and that skepticism took time and consistent outcomes to overcome.”
Laboratory intelligence was extremely significant to the success of this initiative as safe anticoagulation management depends on timely, accurate, and well-interpreted INR monitoring, according to Beena. Laboratory intelligence also informed trend analysis, allowing nurses to detect early deviations, identify causes of instability, and intervene before complications develop.
The model is highly transferable and can be implemented in most healthcare organizations with anticoagulated patient populations, said Beena. The primary requirements are trained nursing staff, standardized protocols, strong collaboration with laboratory medicine and physicians, patient education resources, and a reliable follow-up system. The program does not require expensive technology or additional infrastructure, making it particularly suitable for resource-limited settings.
Enhancing hepatitis C screening
Approximately 50 million people worldwide have chronic hepatitis C infection (HCV). Left untreated, HCV infections can cause cirrhosis, liver failure, hepatocellular carcinoma, and death. Accordingly, the World Health Organization's (WHO's) global strategy for HCV elimination by 2030 aims to achieve a 90% reduction in incidence and a 65% reduction in mortality compared to 2015. A key element to this strategy are direct-acting antivirals (DAAs), which can cure more than 95% of people with HCV infection. Insufficient screening, however, remains the major barrier to HCV treatment and elimination.
The Third Affiliated Hospital of Guangzhou Medical University in Guangzhou, China, developed an HCV care integration model to enhance hepatitis C screening and management to help meet WHO’s expectations. Beginning in 2020, the hospital collaborated with multiple departments as well as community clinics in the Liwan District to screen, transfer, and treat patients with HCV infection.
Since the initiative was implemented, the number of community outreach events more than tripled and HCV RNA testing increased dramatically, from 169 tests in 2020 to 2,201 tests in 2024. Over the course of the 4-year period, 3,219 individuals were diagnosed with an HCV infection, 1,995 individuals received antiviral treatment, and 1,895 were cured.
According to Panpan Zhai, a master of medicine in the department of infectious diseases, the initiative was difficult to implement in the beginning because of communication challenges among the various partners. “However, after thorough and effective communication, we completely cleared the obstacles to collaborative management among the hospital’s departments and connected the community residents, community hospitals, and designated hospitals, achieving a full-cycle, closed-loop hepatitis C management model,” she said.
Almost a third (31.7%) of surveyed patients were referred for testing by relatives or friends following positive experiences related to their HCV care. This type of peer support helps alleviate anxiety among patients and makes them more willing to follow hospital treatment plans, explained Zhai.
Collective mitigated treatment costs for 1% (19) of the cured patients is estimated to range from 950,000 renminbi (RMB) to 7,700,000 RMB (about $142,000 to $1.15 million) based on the potential for early or intermediate diagnosis, assuming median annual treatment costs of 50,000 RMB ($7,462) and 500,000 RMB ($74,629), respectively.
The core of the project’s care process is the “Hospital-Community Health Service Centers-Residents-Family/Friends Pathway,” which ensures direct outreach to target populations with a short and clear route, explained Zhai. “Education serves as a powerful lever, turning participants into trusted peer educators and exponentially expanding the coverage of awareness campaigns,” she said.
The HCV care management project has established an effective collaboration model with standardized processes that can be quickly adapted to communities and hospitals of varying sizes and resources, offering strong scalability. In addition, said Zhai, it provides a replicable framework for screening other infectious diseases, making its application highly versatile.
Optimizing outcomes in patients with CKD
End-stage kidney disease (ESKD) affects an estimated 5.4 million people worldwide. Malaysia has one of the highest incidences of ESKD in the world, largely driven by a high prevalence of diabetes and compounded by an aging population and increasing prevalence of obesity and hypertension, according to Yoke Lee Low, a senior manager with Premier Integrated Labs, in Kuala Lumpur.
Early-stage chronic kidney disease (CKD) is often difficult to identify without routine screening due to its often asymptomatic nature. Consequently, opportunities for early intervention can be limited at a population level. With the goal of supporting early CKD identification and intervention, Premier Integrated Labs in Malaysia launched several initiatives aimed at mitigating CKD progression. In addition to the calculation of estimated glomerular filtration rate (eGFR) using the CKD-EPI equation, they transitioned from the Jaffe Method to the more precise enzymatic method for creatinine measurement in early 2024, while also implementing the Kidney Failure Risk Equation (KFRE) scoring calculation. KFRE aids physicians in stratifying patients according to their risk of progression using four standard variables: age, sex, eGFR, and albumin-to-creatinine ratio (ACR). KFRE and ACR are now included in standard health screening, particularly for those at increased risk of CKD.
“KFRE was selected for its ability to deliver personalized risk prediction that goes beyond eGFR alone,” Low explained. “It relies on readily available clinical variables, allowing us to enhance our services without incurring additional costs. The approach also improves patient outcomes and reduces the overall healthcare burden.”
Prior to implementing KFRE, doctors could only rely on eGFR and ACR, which provided a one-size-fits-all approach to treatment. Using the risk stratification formula, clinicians can now target those who are at high risk for CKD. Using the new formula to screen 9,310 individuals, 3,442 individuals were newly identified as at risk for kidney disease. Of the newly identified high-risk patients, 61% had their medication modified based on this proactive monitoring.
The CKD initiative, which was implemented from April 1, 2024, to October 31, 2025, is projected to generate significant savings of approximately 120 million Malaysian ringgit (RM) per life-year saved (about $30 million), said Low. This is based on an annual savings of 34,791 RMs (about $8,600) per patient for each year dialysis is delayed for 3,442 individuals.
The KFRE is easy to adopt because it is free, globally validated, and requires minimal technical effort, according to Low. This initiative is already being expanded to other labs in Malaysia. Through a strategic partnership with a biopharmaceutical company, the Malaysian Society of Nephrology, and the Malaysian Association of Clinical Biochemists, two additional private laboratories have incorporated KFRE reporting into their lab reports, said Low. The team of five members behind this initiative has been recognized as a 2026 Team of Achievement in association with the UNIVANTS of Healthcare Excellence program.
Fast-tracking hs-cTn results in the ED
Improving patient flow and reducing length of stay (LOS) while maintaining high-quality care are critical priorities for emergency departments (EDs) across health systems. Patients presenting with chest pain represent a large cohort where improvements in these areas could be made. A key consideration is the rapid availability of high-sensitivity cardiac troponin (hs-cTn) results to clinical decision-makers. In 2023, Health New Zealand - Canterbury in Christchurch, New Zealand, implemented a hs-cTn point-of-care (POC) assay in two EDs in the district to help enable result availability and reduce LOS in these EDs. Health New Zealand - Canterbury also supported implementation in four other north island EDs.
The initiative required interdisciplinary collaboration between the ED, the clinical laboratory, and IT departments at a national level, as well as collaboration between multiple hospitals in New Zealand, according to Christopher Florkowski, a pathologist with Christchurch Health Laboratories.
The ICare-FASTER initiative was the first large implementation study of POC hs-cTn globally. The initiative was conceived at the time that the first manufacturers were applying for accreditation for their POC hs-cTn assays, which is why Christchurch Health Laboratories needed to evaluate the assay’s analytical characteristics and quality control material for suitability of use in multiple settings, in addition to establishing a single-sample rule-out threshold before the assay could be used for clinical care. The initiative is highly unique in that the diagnostic pathways developed were the first to incorporate a hs-cTn POC assay and the first to incorporate two troponin assays.
“It required major input from point-of-care coordinators to train ED nurses as end users of point-of-care devices,” Florkowski explained. “The process also involved verification of the POC devices and a clinical outcome study to determine appropriate troponin thresholds for the pathway as a prelude to ICare-FASTER itself. The implementation and evaluation study ran over several years and is the fruition of an initiative put forward several years previously.”
Implementation of the hs-cTn POC assay substantially reduced LOS at Christchurch Hospital, the largest in Australasia, by 11%, while LOS at Ashburton, a small regional hospital, dropped by 35%.
Reducing health inequities between the indigenous Māori people of New Zealand and others is a key government priority, so the implementation team paid special attention to how the new test affected the Māori. At Christchurch Hospital, the LOS for Māori declined by 16% while at Ashburton Hospital, it declined by 22%.
“Overall, data from ICare-FASTER have shown a reduction in mean ED length of stay, which is highly significant when extrapolated over a longer period of time and contributes to a reduction in ED overcrowding,” Florkowski said. “While not completely alleviating the situation, it has made a significant contribution.”
For their efforts, the Health New Zealand - Canterbury team was recognized as a 2026 Team of Achievement through the UNIVANTS program.
Optimizing magnesium reference values
Chronic magnesium deficiency (hypomagnesemia) affects 3% to 10% of the global population, but it is frequently overlooked. Underdiagnosis largely stems from the use of broad, generic reference intervals commonly adopted from values provided in reagent package inserts or analytical kit manuals, without adjustment to the specific characteristics of the local population.
In response to this diagnostic gap, professionals in laboratory medicine and biostatistics in Brazil conducted a population-based validation study to establish serum magnesium reference intervals that reflect the real health profile of the local outpatient population. A total of 144,823 serum magnesium test results were analyzed from 2022 to 2024, which included both sexes and a wide range of ages. Three diagnostic criteria were compared: generic values indicated in reagent package inserts (1.3-2.7 mg/dL); literature-based values (1.7-2.4 mg/dL); and population-based values defined from the Brazilian dataset (1.6-2.4 mg/dL).
The study found that mean serum magnesium levels showed a consistent decline with age, and only 0.5% of individuals reported magnesium supplementation. The adoption of different reference levels profoundly affected diagnostic performance. The generic criterion identified only 0.2% of hypomagnesemia cases, indicating a substantial underestimation. The literature-based criterion detected 4.3%, aligning with international expectations. The new population-based criterion identified 2.1%, effectively doubling the diagnostic yield compared with the traditional approach.
Of those studied, 2,796 patients who would have previously been classified as having normal serum magnesium levels were reclassified as hypermagnesemic after adoption of the population-based upper limit (2.4 mg/dL), enabling more targeted clinical attention. Of those, 2,269 patients (73.07%) were over 60 years old. Altogether, 1.9% more patients with hypomagnesemia were identified, a 10-fold improvement in detection.
“These findings demonstrate that revising the reference intervals within the laboratory setting leads to measurable improvements in diagnostic accuracy,” said Adria Gadelha Ferreira dos Santos, a medical student with Emilo Ribas Medicina Diagnostica, a private laboratory in Fortaleza, Brazil. Early detection of magnesium deficiency enables timely clinical interventions and may prevent complications, such as impaired glucose control, cardiovascular instability, and arrhythmias.
This initiative, which was recognized in 2026 as a Team of Achievement, demonstrates that generic reference values fail to adequately represent the biological diversity of local populations, explained Gadelha. By adopting locally validated, data-driven reference intervals, laboratory medicine reinforces its central role as a bridge between diagnostic technology and precision clinical care.
“For patients, the impact of this initiative is both significant and measurable,” said Gadelha. “By redefining serum magnesium reference values based on the local population, the laboratory achieved a 10-fold improvement in the detection of hypomagnesemia, identifying 1.9% more patients who would have previously gone unrecognized.”
Enhanced IBD diagnosis and care
Colonoscopy remains the gold-standard for diagnosing inflammatory bowel disease (IBD), but it is invasive, resource-intensive, and associated with patient discomfort, procedural risks, and significant cost. An integrated clinical care team at King Fahad Specialist Hospital in Dammam, Saudi Arabia, recognized that many patients undergoing colonoscopy for suspected IBD could first be assessed using a reliable, noninvasive biomarker to help avoid unnecessary colonoscopies, according to Najla Khalid Al Mahbashi, allied health director in laboratory medicine for the hospital.
“Our multidisciplinary team introduced fecal calprotectin (FC) as a first-line triage tool to help distinguish patients who were more likely to have intestinal inflammation and genuinely required further endoscopic evaluation,” Mahbashi explained. “The aim was not to replace colonoscopy when clinically indicated, but to use it more appropriately by reducing unnecessary procedures while maintaining timely access for patients at higher risk of IBD.”
Values below 50 µg/g effectively rule out IBD, 50-150 µg/g represent a borderline zone warranting
repeat testing or clinical assessment, and levels above 150 µg/g indicate likely active intestinal inflammation and are used to prioritize endoscopic assessment in symptomatic patients, particularly at initial presentation or when symptoms persist despite therapy.
The initiative required coordinated changes across laboratory medicine, gastroenterology, and clinical care teams. Key implementation priorities included clinician engagement, agreement on standardized FC cutoff values and referral criteria, integration of in-house testing into routine practice, and consistent communication of results and interpretation. The new model also established a fully electronic, closed-loop workflow in which FC orders and results were captured, traceable, and immediately accessible through the electronic medical record (EMR). Patient education remained important, particularly regarding stool sample collection and the role of FC testing in the diagnostic pathway.
Between September 2023 and November 2025, 1,115 FC tests were performed on 630 patients. Colonoscopy utilization within 90 days of FC testing was 8.1%, compared with an estimated 30%–35% utilization without FC-based triage. This was associated with approximately 170 avoided
colonoscopies and an average annual direct procedural cost mitigation of 1.2 million Saudi Riyals (about $320,000), excluding anesthesia, consumables,
and bed-utilization costs.
Bringing FC testing in-house also reduced the average turnaround time from 26 days to 5.31 days — an improvement of approximately 80%. Faster and more reliable result availability supported earlier clinical decision-making and contributed to a two-fold increase in the number of clinicians using FC testing in routine evaluation of patients with gastrointestinal symptoms.
“The findings demonstrate that a simple laboratory biomarker can produce meaningful clinical, operational, and financial benefits when incorporated into a well-designed multidisciplinary pathway,” Mahbashi said. The initiative was recognized as a 2026 Team of Achievement by the UNIVANTS of Healthcare Excellence program.
The pathway is highly transferable and scalable. Institutions would need access to a validated FC assay, an agreed-upon clinical algorithm with clearly defined cutoff values and referral criteria, and effective collaboration between the laboratory, gastroenterology, primary care, and other referring clinical teams.
“Successful implementation also requires clinician and patient education, standardized sample collection instructions, clearly defined expectations for patients with alarm symptoms or other indications for colonoscopy, and ongoing monitoring of clinical and financial outcomes,” Mahbashi said.
Laboratory leadership drives better care
Each of these initiatives demonstrates the criticality of clinical laboratories in improving screening, diagnosis, and intervention, all of which are linked to improved patient outcomes. Beyond simply providing test results, labs are increasingly taking an active role in helping diagnose illnesses before they progress. For details on these winners and others, go to UnivantsHCE.com.
Kimberly Scott is a freelance writer who lives in Lewes, Delaware. +Email: [email protected]
UNIVANTS 2026 teams spotlighted in this issue
TEAMS OF DISTINCTION
Transforming cervical cancer screening: A novel, high-resolution genotyping strategy using self-collected samples to enhance access and system equity
Bergen New Bridge Medical Center
Paramus, New Jersey, United States
Ilham Atir
Katie Richardson
Charlsie Celestine
Diane Darmody
Raquel Ortiz
Improving patient wellness and mitigating healthcare costs through BNP-guided detection of previously unknown heart failure risk
Izumi City Medical Association
Izumiotsu, Japan
Akihisa Hanatani
Hidemasa Tanaka
Shuzo Nagata
Yoshio Kawase
Naotsugu Takahashi
Nurse-led anticoagulation clinic for improved safety and reduced complications in patients taking oral anticoagulation
KIMSHEALTH Trivandrum
Trivandrum, India
Beena C. A.
Samitha Nair
Remya R.
Francis Cruz
Jayasree N. S.
Enhancing hepatitis C screening and management through community-driven bidirectional care integration
The Third Affiliated Hospital of Guangzhou Medical University
Guangzhou , Mainland China
Honghai Hong
Xingfei Pan
Yong Xia
Kewei Dai
Meiling Liu
Panpan Zhai
TEAMS OF ACHIEVEMENT
Increasing awareness and improving wellness through KFRE-guided screening and management of chronic kidney disease
Premier Integrated Labs Sdn Bhd
Kuala Lumpur, Malaysia
Yoke Lee Low
Hareeff Muhammed
Leslie Charles Lai Chin Loy
Fong Voon Ken
Sarania Sukumaran
Improving care by faster risk-stratification through use of high sensitivity point-of-care troponin in patients presenting with possible acute coronary syndrome in the emergency department
Health New Zealand - Canterbury
Christchurch, New Zealand
Christopher Florkowski
Martin Than
John Pickering
Vanessa Buchan
Laura Joyce
Application of populationbased magnesium reference values for increased detection of abnormalities
and improved patient wellness
Emilio Ribas Medicina Diagnóstica
Fortaleza, Brazil
Adria Gadelha Ferreira dos Santos
Lais Farias Masullo
Waneska Freitas Nobre
Sandra Pereira dos Santos
Rachel Petrola Jorge Bezerra
Reducing unnecessary colonoscopies and enhancing value-based care through fecal calprotectin-guided IBD diagnosis and management
King Fahad Specialist Hospital
Dammam, Saudi Arabia
Najla Khalid Al Mahbashi
Bahaa Farouk Bseiso
Batool Alsaeed
Ayedh Saad Ayedh Alqarn
Saad Ahmed Mohammed Aldaama